Tag: Immunotherapy
-
The Promise of Immunotherapy to Cure HIV
Introduction: A Shift from Suppression to Cure For years, antiretroviral therapy (ART) has transformed HIV from a fatal disease into a manageable condition. It suppresses the virus to undetectable levels, allowing people living with HIV to lead longer, healthier lives. Yet ART does not eradicate HIV. The virus persists in latent reservoirs, and if treatment…
-
Latin America’s First Homegrown CAR-T Center Opens in Ribeirão Preto, Promising Lower Cancer Care Costs
Introduction: A Milestone for Latin America’s Public Health In a landmark move for Latin America, Ribeirão Preto welcomes the Nutera Center, the region’s first homegrown CAR-T (Chimeric Antigen Receptor T-cell) therapy program. Backed by significant public investment, the center aims to expand access to cutting-edge cancer treatment while driving down costs for Brazil’s public health…
-
NICE Recommends AUCATZYL (obecabtagene autoleucel) for UK patients
Summary: NICE backs AUCATZYL for eligible patients The National Institute for Health and Care Excellence (NICE) has recommended AUCATZYL, the CAR-T cell therapy obatabtagene autoleucel (also known as obecabtagene autoleucel), for use within the UK’s healthcare system. The decision marks a significant milestone for patients with certain hematologic cancers and highlights the growing role of…
-
Immunotherapy Advances in SCLC: Promise, Limits, and the Biomarker Challenge
Current gains from immunotherapy in small cell lung cancer (SCLC) Immunotherapy has altered the treatment landscape for SCLC, offering meaningful efficacy where options were once limited. Checkpoint inhibitors that unleash the body’s immune system to attack cancer cells have demonstrated survival benefits in certain patients and disease settings, particularly when used in first-line combinations or…
-
Immunotherapy Advances in SCLC: Promise, Limitations, and the Biomarker Gap
Immunotherapy Advances in Small Cell Lung Cancer (SCLC): A Quiet but Persistent Shift Small cell lung cancer has long challenged clinicians with its aggressive biology and historically limited treatment options. In recent years, immunotherapy has emerged as a meaningful, if nuanced, addition to the standard of care. The story is not a single triumph but…
-
Immunotherapy Advances in SCLC: Promise, Limitations, and Biomarker Needs
Overview: Immunotherapy’s Emerging Role in SCLC Small cell lung cancer (SCLC) has long challenged clinicians with its aggressive biology and tendency for rapid relapse. In recent years, immunotherapy has emerged as a beacon of hope, offering meaningful efficacy gains in several lines of treatment. This article reviews the current state of immunotherapy in SCLC, highlighting…
-
Compugen Announces Q3 2025 Results Highlighting COM701 ESMO 2025 Data and MAIA-Ovarian Platform Trial Progress
Overview of Q3 2025 Results Compugen has released its third-quarter 2025 results, underscoring continued momentum in its oncology pipeline and the strategic progress of key clinical programs. The company reaffirmed its commitment to advancing targeted cancer therapies, with a particular focus on COM701 data presented at ESMO 2025 and the ongoing expansion of the MAIA-ovarian…
-
Nanovaccine Shows Promise in Treating HPV-Related Cancers
Breakthrough in HPV-Related Cancer Treatment Scientists at UT Southwestern Medical Center report that a nanoparticle-based vaccine designed to combat cancers caused by the human papillomavirus (HPV) has demonstrated dramatic effects in preclinical studies. The vaccine, built on a nanotechnology platform, target’s HPV-triggered tumors and appears to stimulate the body’s immune system to attack cancer cells…
-
Innovent Highlights: General Biomedicine Pipeline Showcased at 2025 ACR Annual Meeting
Innovent Unveils Progress Across the General Biomedicine Pipeline at the 2025 ACR Annual Meeting The 2025 ACR Annual Meeting in San Francisco and nearby venues became a hub for researchers and industry leaders as Innovent Biologics, a global biopharmaceutical company, highlighted several milestones from its General Biomedicine Pipeline. The presentations underscored a commitment to advancing…
-
Immune Complications Drive Higher Infection Risk in Advanced Myeloma Therapies
Overview: A New Frontier in Multiple Myeloma Treatment Chimeric Antigen Receptor (CAR T-cell) therapy and bispecific antibody (BsAb) therapy have transformed the management of advanced multiple myeloma (MM). These immunotherapies mobilize the patient’s own immune system to target and destroy malignant plasma cells, offering durable responses for many who have exhausted conventional therapies. Yet, with…